Title

Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analysis in the Cholesterol and Recurrent Events (CARE) trial .

Purpose

To determine whether pravastatin prevented recurrent cardiovascular events in diabetic patients

Design

As per CARE trial

Patients

586 patients in the CARE trial with diabetes

Follow-up

5 years

Treatment regimen

As per CARE trial

Results

• Pravastatin reduced LDL cholesterol by 27% in the diabetic group and 28% in the nondiabetic group.
• Pravastatin induced a 25% reduction in coronary events (coronary heart disease death, nonfatal myocardial infarction,
CABG and PTCA) p=0.05; it reduced the risk for revascularisation procedures by 32% (p=0.04). Because of a greater
coronary event rate in the diabetic group, pravastatin resulted in a greater absolute risk reduction in diabetic vs nondiabetic
group (8.1% vs 5.2%) .

Conclusion

Both diabetic and nondiabetic patients with elevated fasting glucose levels are at risk for recurrent coronary events post infarction; pravastatin can reduce these events.